AlphaFold predicted structure
PRDM6 · Q9NQX0

Mean pLDDT
56.2/ 100
Low
595 residues
Confidence breakdown
- Very high(≥ 90)3%
- Confident(70–90)33%
- Low(50–70)17%
- Very low(< 50)47%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
PR/SET domain 6
Annotations refreshed 1 month ago.
Moderate Evidence (Amber)
Paediatric disorders - additional genes
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedDDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownpersistent fetal circulation syndrome
hypertensive disorder
neurodegenerative disease
essential hypertension
androgenetic alopecia
aortic aneurysm
Increased blood pressure
cardiovascular disorder
familial patent arterial duct
aneurysm
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Putative histone-lysine N-methyltransferase PRDM6
Putative histone methyltransferase that acts as a transcriptional repressor of smooth muscle gene expression. Promotes the transition from differentiated to proliferative smooth muscle by suppressing differentiation and maintaining the proliferative potential of vascular smooth muscle cells. Also plays a role in endothelial cells by inhibiting endothelial cell proliferation, survival and differentiation. It is unclear whether it has histone methyltransferase activity in vivo. According to some authors, it does not act as a histone methyltransferase by itself and represses transcription by recruiting EHMT2/G9a. According to others, it possesses histone methyltransferase activity when associated with other proteins and specifically methylates 'Lys-20' of histone H4 in vitro. 'Lys-20' methylation represents a specific tag for epigenetic transcriptional repression
Curated MONDO disease pages that list PRDM6 among their top associated genes.
PRDM6 · Q9NQX0

Mean pLDDT
56.2/ 100
Low
595 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0